Thank EPS quarter, year-over-year basis growth you, record XX%, LabCorp morning. of of expansion operating growth adjusted with of adjusted margin X%. points revenue the in and Scott, XX and results good third delivered
of We us nearly record free outlook $X also to solid a reported enabling to billion. another cash raise new flow, quarter of year our full
hurricanes. women’s acquisition medical our results, our to volume the collaboration Chiltern, from with basis shareholders. of quarter, growth by outstanding broad-based, drug organic we monitoring deployment, on the led strategic the XXandMe. Diagnostics, by drag XXX health, the given impressive have robust was driven more with impact and of the of During growth continued even we active points of and strategic In remained Organic growth, and highlighted approximately by return total capital capital
PAML business as our to integration In performance. outreach addition, Sinai’s Mount are strong the and proceeding of contributing planned,
impacted in substantial regions in performed employees swiftly our for any face specimens. of operations collected adversity, operations remarkably multiple the restoring disruption of the processing and without Speaking in the team hurricanes, patients our
our affected communities of quarter, their development, areas. book-to-bill relief versus to orders need. generously behalf and a we and our patients In for continuation net of for appreciate the and had XX-month outstanding drug highlighted by X.XX All contributed each efforts of colleagues in other at X.XX improving trailing on also We to year-end efforts strong a XXXX. solid
team XXXX. positioning We continue line grow organically to performance in business historical capabilities, the our in and invest to its strategically in expand with
hospital independent laboratories, intent that designed of higher-price it demonstrated, is as the Medicare report its XXXX in much also when reports continue from service as consumes CMS place. X of apparently to commercial typically CMS Medicare strategic their significantly comment to commercial to to the of labs. paid labs update have physician on of its to beneficiary find data? instructed in a and desirable priorities, has published office We that be X% goal to key that the overlooked disappointing is warning of intent. pricing. the appropriate, briefly last Thus, work Congress to in that critical with X,XXX actions Before to rates. and charge preliminary their anywhere lab the disappointing X.X possible hospital independent times We entire no reported to hospitals that I CMS OIG were badly industry, reduced specifically in the customers fewer not include labs office X% that missed expected labs, for on by proposed even Congress deeply over-weighted to board How which I spending CMS ignoring congressional surprising country implement will Market the and not pricing which entire as for CMS, the our laboratory of market-based remedies, explore the testing. PAMA stakeholders laboratory market-based expressed we attempt Unfortunately, determined closely for critical in the access continue laboratories and determine the commercial and services. aligning you repeatedly market. PAMA. will action hospital to actions with In a price may as market expressly PAMA, reflect In we the only pricing legal submitted overlooked dialogue CMS’ do physician survey Medicare, highlight only clearly labs focused the by all in was Medicare as unmerited and survey month vastly they, CMS and we rates have mark services. cuts including industry stated statutory pricing first on and rates again It could comments than first the Congress’ XX fact, so reported is implementation represent
our progress key priorities, with our of you the focused development. drug update on will on I Now initiatives and strategic combination on beginning Diagnostics
patient real-world data innovative and global physician Covance’s recruitment the and that combination investigator performance patient We utilize into of provider solutions and studies to data. continue advance LabCorp Diagnostics’
we During the based quarter, capability. unique on awards multiple this won
to ulcerative quarter ulcerative global indication-specific selected be about engaged provided Covance the individuals study. a to outreach in patients contacted has We bid Using previously study used number competitive in total For that placed LabCorp bilirubin, has to an antibody trial this patients disease Covance. such and involved award. clinical to of parameters we the II have being been a lab sponsor LabCorp colitis by their had mitochondrial example, to the were for previously population, sponsor resulting followed another Covance. in we Phase for who interested consent in a conduct process liver conducting global In that biopharmaceutical we large previously not the example, a and not secured patient matched level the opportunities, sponsor’s protocol of against potential potential up colitis protocol-eligible study identified identification a as run criteria active
direct for Covance’s for engagement that continue with becoming clinical and physicians, patients trials. expressed we closely and have preferred in with LabCorp to interest health work Beyond systems partners
agreements form such signed recruitment, populations health patient efficiency diverse We and which partnerships, with have and to health will enhance our deepen increase system several systems relationships. access patient major broad-based to
customers. our broad $XX go-to the have to capabilities companion complementary and year-on-year lead unique continue industry and established pharma from awards delivered a in mix double-digit LabCorp We and growth in as around revenue than new capabilities precision medicine. partner of diagnostics. quarter won We more in of the biotechnology These another million
Excellence Diagnostics into cell Oncomine Thermo the with entered and agreement patients. we Scientific its Center to have launched Fisher program, target we panel cancer lung quarter, of the for Fisher join Dx Thermo an NGS During Companion non-small
and We to U.S.-based tumor tests, also oncology entered offering OmniSeq’s to immune profiling distribute agreement and into profile strengthening our global biopharmaceutical physicians an exclusive customers.
drug important addition in In strong successes Diagnostics, In this business and and enterprise-wide consumer progress delivered to Diagnostics quarter. we patient-facing progress our development initiatives, both on made initiatives.
start. Our LabCorp-Walgreens collaboration off to terrific is a
volumes, We Scores pleased on feedback these with are patient at sites. the Promoter and patient experience Net
to expect to XXXX. We LabCorp-Walgreens expand additional in sites
to continue of progress our strategy. consumer We elements make other in
card PSCs that allows solution automatically Express, in scans customer’s and are insurance patients driver’s select at We check LabCorp a tablet license. through to that custom-built a the introducing
PSC. application, insurance convenience streamlining reduce information patients debt demographic by opportunities of and to experience quality also improving trial PSC complete that These wait a about enhance which clinical web learn collect helping bad for to we mobile-optimized times, by workflow, create the reducing patients more patient to deployed and prior patients’ and steps We solutions PreCheck, verification at to allows LabCorp our the arrival opportunities.
and The Chiltern has revenue customer to of Chiltern expertise add to and Covance. Chiltern start, download enhanced also will our development. year, closed solutions on drug driving in a and integration enhanced Asia available new In welcome off operational in capabilities for launch into The We segment, version of trials our accelerating next FSP complementary mobile clinical and device reach September growth capabilities LabCorp of mid-tier stores. through the Patient profit and capabilities. and app various future acquisition emerging growth including business, drug are scale excellent development warmly at oncology biopharma position is in highly strategic early app strengthening Pacific, will Xst, profitable offering, fast-growing our broader colleagues. and we significantly Chiltern on our be which we an expanded focused development medical within
profitable Our focus investments growth on encompasses organic strategic as as acquisitions. well
laboratory and the serve FDA network completed important our investment of to supplies and provide and chemistry For XX a facility development cost-effective new The disease nine as more ability diseases our C, outside enhance X,XXX as our the used scheduled operations biologics arthritis, central therapies large-molecule business lab faster, of the open XX this Belgium. past of trial rheumatoid and Mechelen, by approved more life-changing manufacturing customers biologics center later the than new packages, expanded in year. Crohn’s analytical by has XXXX. central comprehensive site clinical This years growing market. production This in drug consolidation and opening control allows and of in treatment kits supported a to biopharmaceutical alone, cancer. and submission the U.S. Covance four to hepatitis more planned such than other including integrated We will In of Covance’s is for ability example, to enhances European delivery our our of this capabilities investment
progressing Covance Finally, our LaunchPad well. initiative is
customer solutions, enterprise-wide recognized tier policy experience ongoing and integrate clinician our Last month, new for joined sustainably and leadership us increase a strategic top plans Underpinning Caveney our finalizing is who North progress Brian Officer. of and our reengineer the LabCorp Medical investment strong Shield Dr. welcomed Cross we Blue from tools are and our We longer-term in Caveney as Dr. in development our health enhance Carolina. is priorities projects key and Blue nationally to margins. technology, expert to drug talent. Chief
Dr. exemplary to the of In succeeds Mark United his Brecher, Adcock, announced coagulation promote the Medical Dorothy who intention States, of in foremost addition, after Diagnostics’ Chief to of are Dr. pathologists LabCorp we pleased the to eight retire Adcock service. Officer. one years Dr. role
Dr. our morning his New and event as in LabCorp. you investors initiatives, with our see to success key years experience to with you To opportunity of the innovation our to The In expertise, pleased to projects, analysts hear we City. to our leaders, for for grateful strategic experience February provide team important are and an we well XXXX, of our to performance learn directly and strategy on the with of hope XX, York many for closing, We more contributions Brecher demonstration the an and will quarter there. in about differentiators LabCorp. are from long-term deeply as optimistic a hold key are about We vision ahead.
XX,XXX than innovative employees, to customers. world continues advancing more growth to customers, to to Thanks health available substantial motivated only to employees LabCorp range We and our the deliver who shareholders. the wide and mission initiatives, solutions from around significant of continue by lives, partners make are key LabCorp dedication value patients, progress improve to strategic on a of improve
Now the call to I’ll turn Glenn. over
